Diversified Trust Co Purchases 4,348 Shares of Insulet Co. (NASDAQ:PODD)

Diversified Trust Co lifted its position in shares of Insulet Co. (NASDAQ:PODD) by 90.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,130 shares of the medical instruments supplier’s stock after purchasing an additional 4,348 shares during the period. Diversified Trust Co’s holdings in Insulet were worth $1,842,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in PODD. Benjamin F. Edwards & Company Inc. purchased a new position in Insulet during the fourth quarter valued at approximately $34,000. Sunbelt Securities Inc. purchased a new stake in shares of Insulet during the first quarter valued at approximately $29,000. Jones Financial Companies Lllp bought a new position in shares of Insulet in the fourth quarter worth approximately $40,000. Lindbrook Capital LLC increased its stake in shares of Insulet by 64.1% in the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after buying an additional 75 shares during the period. Finally, CVA Family Office LLC raised its holdings in Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 145 shares during the last quarter.

Insiders Place Their Bets

In related news, SVP Mark N. Field sold 1,500 shares of the stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the sale, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at approximately $2,574,485. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Timothy J. Scannell sold 3,300 shares of the stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $180.90, for a total transaction of $596,970.00. Following the sale, the director now directly owns 42,586 shares of the company’s stock, valued at approximately $7,703,807.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mark N. Field sold 1,500 shares of the stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the sale, the senior vice president now directly owns 12,875 shares in the company, valued at $2,574,485. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,931 shares of company stock valued at $2,636,286. 0.47% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on PODD shares. Canaccord Genuity Group restated a “buy” rating and issued a $234.00 price objective on shares of Insulet in a research report on Tuesday, July 23rd. Raymond James lowered their price target on Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a research report on Friday, May 10th. Redburn Atlantic began coverage on Insulet in a report on Thursday, May 30th. They issued a “buy” rating and a $235.00 price objective for the company. UBS Group boosted their target price on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Finally, Jefferies Financial Group raised their price target on Insulet from $255.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, May 10th. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $232.13.

Insulet Stock Up 0.1 %

NASDAQ PODD traded up $0.12 during trading hours on Wednesday, reaching $194.71. 26,947 shares of the company’s stock traded hands, compared to its average volume of 839,671. Insulet Co. has a 52-week low of $125.82 and a 52-week high of $227.55. The company has a debt-to-equity ratio of 1.72, a current ratio of 3.74 and a quick ratio of 2.75. The firm has a 50-day simple moving average of $196.65 and a 200 day simple moving average of $183.70. The firm has a market cap of $13.64 billion, a PE ratio of 58.97, a PEG ratio of 3.53 and a beta of 1.16.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). The business had revenue of $488.50 million for the quarter, compared to analysts’ expectations of $488.00 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. Insulet’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.38 earnings per share. Sell-side analysts anticipate that Insulet Co. will post 3.11 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.